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Abstract Objective
To review the evidence for the efficacy and safety of colchicine in children with pericarditis.
Design

Systematic review
Search strategy
The following databases were searched for studies about colchicine in children with pericarditis (June 2015): Cochrane Central, Medline, EMBASE and LILACS.
Eligibility criteria
All observational and experimental studies on humans with any length of follow-up and no limitations on language or publication status were included. The outcomes studied were recurrences of pericarditis and adverse events.
Data extraction
Two authors extracted data and assessed quality of included studies using the Cochrane risk of bias tool for non-randomized trials.
Results
Two case series and nine case reports reported the use of colchicine in a total of 86 children with pericarditis. Five articles including 74 paediatric patients were in favour of colchicine in preventing further pericarditis recurrences. Six studies including 12 patients showed that colchicine did not prevent recurrences of pericarditis.
Limitations
No randomised controlled trials were found.
Conclusion
Although colchicine is an established treatment for pericarditis in adults, it is not routinely used in children. There is not enough evidence to support or discourage the use of colchicine in children with pericarditis. Further research in the form of large double-blind randomised controlled trials is needed to establish the efficacy of colchicine in children with pericarditis.
INTRODUCTION
Pericarditis is the inflammation of the pericardium, the membranous sac surrounding the heart. Pericarditis is idiopathic in 80% of cases, however it is presumed to be viral in origin 1 . Other causes of pericarditis include post-pericardiotomy syndrome, tuberculosis or bacterial and neoplastic diseases 2 . Post-pericardiotomy syndrome is a more common cause in children than in adults 3 .
The incidence of pericarditis is 2-3 in every 1000 hospitalised children Colchicine has been shown to be effective in preventing recurrent episodes in adults [6] [7] [8] [9] , however it is not routinely used in children 10 . The objective of this systematic review was to identify the efficacy and safety of colchicine in children.
METHODS
This systematic review was registered in the international database of prospectively registered systematic reviews in health and social care (PROSPERO) on the 20th July 2015 (registration number: CRD42015024647) 11 .
Data Sources
The following databases were searched (from their start to June 2015): Cochrane Central, Medline, EMBASE and LILACS. The search did not include any language or time restriction.
The search strategy was designed for maximum sensitivity using the Boolean operator AND to combine all synonyms for colchicine with all possible ways of referring to pericarditis. (See appendix 1 for full details.) In addition, bibliographic references of identified articles were reviewed. We searched www.clinicaltrials.gov for on-going trials on 14th February 2016.
Eligibility Criteria
Although randomised controlled trials (RCT) are the best way to test treatments, we anticipated that we would not find many. Therefore our eligibility criteria were any study design of pericarditis in children treated with colchicine. There was no limitation on length of follow-up, language or publication status.
Outcomes 1) Efficacy of colchicine in treating children with pericarditis, defined as prevention of recurrences or symptom relief.
2) Adverse effects and tolerability of colchicine in children.
Data extraction and analysis
Two authors independently screened titles and abstracts for inclusion. The opinion of a third author was sought when an agreement could not be reached. Full-text publications were obtained for included studies or where eligibility was unclear from the title and abstract. Two authors extracted data and assessed quality of included studies using a pre-defined data collection form.
We adopted the Cochrane risk of bias tool for non-randomized trials (ACROBAT-NRSI) to assess the quality of included studies 12 . The tool assesses domains of confounding, selection of participants, outcome measurement, missing data and follow-up.
Subgroup analysis
We planned to analyse dose regimens used and duration of treatment.
RESULTS
A total of 352 records were identified. Removal of duplicates left 266 articles for screening. A total of 68 full texts were assessed for eligibility and 11 articles met the inclusion criteria (Figure 1 ). No additonal study was found through the manual search of bibliographic references of the retrieved papers. No ongoing clinical trials were found on clinicaltrials.gov.
Study Characteristics
Two case series 13, 14 and nine case reports 4, [15] [16] [17] [18] [19] reported the use of colchicine in a total of 86 children with pericarditis.
Studies reported children with different severities of pericarditis. Three studies (two case reports and one case series) were in children with post-pericardiotomy syndrome 13, 20, 21 .
The study characteristics are given in table 1.
Quality of included studies 1) Selection of participants Two case series were included. Consecutive inclusion of patients was reported in one of the studies 14 , while we could not tell if all consecutively patients were included in the other case series 13 .
2) Risk of bias of confounding.
No included study pre-specified a list of potential confounders of pericarditis therapy. No study carried out statistical modelling for confounding factors or adjusted for time-varying confounding.
We could not tell from the included reports if confounding factors such as indication of treatment, additional therapies, type of pericarditis and age of children, affected the effect of colchicine.
3) Outcome measurement and assessment
Methods for collecting data were poorly reported and we could not tell if any of the studies used more than one outcome assessor to repeat the analysis to ensure reliability.
None of the included studies had control groups. Findings were reported as recurrence free period after colchicine. Two studies reported pre-and post-colchicine recurrence rate 13,14 .
4) Missing data
The included papers did not report incomplete or missing data. We could not tell if this because of lack or reporting or absence of missing data. However, the included case reports had appropriate follow up of 6 -24 months (Table 1) .
Two articles were only available as conference abstracts 14, 17 which limited the amount of data available.
Efficacy of colchicine or pericarditis in children
Included studies were heterogeneous in populations, study designs and outcome reporting; we therefore did not pool data in a meta-analysis. The findings of the included studies are described below. Two types of pericarditis were studied: idiopathic pericarditis and post-pericardiotomy syndrome.
A detailed data extraction of all included studies is given in Appendix 2.
Idiopathic Pericarditis
Seven case reports 4, [15] [16] [17] [18] [19] 22 and one case series 14 reported the use of colchicine in children with idiopathic pericarditis.
The case reports included 12 children with a median age of 11.5 (range 2-14) and 70% male gender distribution. All children had multiple recurrences of pericarditis while treated with NSAIDs and steroids. When colchicine was added, 7 out of 12 children (58%) had no further recurrences, while the other 5 (42%) continued to have recurrences. The median follow up was 12 months (range 6 -60). The included articles did not report the exact number of pericarditis recurrences pre and post colchicine treatment.
The case series was only available as an abstract and included 100 children with a median age of 13 (range 1 -17) and 62% male gender distribution. Colchicine was added to NSAIDs or steroids in 67 patients (67%). The median follow up was 60 months (range 6 -360 months). The number of pericarditis recurrences per year was 3.8 before colchicine was given and 1.6
afterwards.
Post-pericardiotomy syndrome
One case series 13 and two case reports 20, 21 reported the use of colchicine in children with postpericardiotomy syndrome. 
DISCUSSION
Colchicine is an established treatment for pericarditis in adults [6] [7] [8] [9] . It's efficacy to reduces recurrences and help relieving symptoms has been proven in a number of RCTs [24] [25] [26] [27] [28] [29] . However, no RCT has been carried out in children 30 and there are no ongoing trials. We estimate that a RCT with 82 children is needed to detect the same pericarditis recurrence risk reduction as in adults (for 5% significance level and 80% power). children were in favour of using colchicine to prevent further pericarditis recurrences.
These children had mainly an idiopathic pericarditis. On the other hand, one case series 13 and five case reports [18] [19] [20] [21] [22] including 12 children showed that colchicine did not prevent recurrences. Three of these studies were in children with post-pericardiotomy syndrome 13, 20, 21 . Two studies 18, 19 reported children with pericarditis resistant to colchicine but responded to the use of interleukin-1b receptor antagonist (anakinra).
Studies reported that colchicine was well tolerated in children although the small number of included children might not be representative. It is noted that colchicine is not licensed in either the USA or Europe for the use in pericarditis 31 .
LIMITATIONS
Very little is reported on the use of colchicine in children in the medical literature. Included studies are case series and case reports only, therefore the conclusions of this review are based on low quality evidence. Two articles were only available as abstracts 14, 17 .
Nine of the twelve included studies were reported from centres in the Mediterranean region (Italy, Spain, Lebanon and Israel) 4, [14] [15] [16] [18] [19] [20] [21] [22] . This is similar to the situation in adult studies where all randomized controlled trials of colchicine in pericarditis were done in Italy 31 . It is possible that the findings may not apply to groups from other climates or geographical locations.
Two studies reported pre-and post-colchicine recurrence rate to report colchicine efficacy in preventing recurrences 13, 14 . However, this conclusion is not appropriate as there was no control group and it was not possible to tell what the recurrence rate in the same population would have been without colchicine.
CONCLUSIONS
The available literature suggests that colchicine might be effective in preventing recurrences in children with idiopathic pericarditis, however the quality of evidence is very low.
Taking into account that colchicine is cheap to produce and effective in adults, it is important that its efficacy in children with pericarditis is tested further in the form of large double-blind randomised controlled trials.
"What is already known on this topic" Two in every thousand hospitalized children experience episodes of pericarditis. Recurrent episodes can occur in up to 30% of the affected children, severely impairing their quality of life. Colchicine has been shown to be effective in adults.
"What this study adds"
There is need for large double-blind randomised controlled trials is needed to establish the efficacy of colchicine in children with pericarditis
